espite being preventable and curable, tuberculosis (TB) is the world’s deadliest infectious disease, killing 1.6 million people every year—more than HIV/AIDS and malaria combined. Underserved communities bear the largest burden, with more than 95% of TB-related deaths occurring in low- and middle-income countries, but this airborne disease knows no borders.

Growing drug resistance is compounding this public health challenge. In 2017, there were nearly 500,000 new cases of multidrug-resistant TB (MDR-TB), which does not respond to the two most frequently used first-line TB drugs. Drug-resistant TB now accounts for nearly one-third of all deaths from antimicrobial resistance (AMR).

For nearly 20 years, both in our laboratories and on the ground in countries impacted by TB and MDR-TB, Johnson & Johnson has been supporting global efforts to end TB and combat AMR.

Our Mission: Enabling a World Without TB
Our Mission: Enabling a World Without TB
In 2012, our medicine for pulmonary MDR-TB was granted accelerated approval by the United States Food and Drug Administration (U.S. FDA) for use as part of a combination therapy in adults when an effective treatment regimen cannot otherwise be provided. This was the first targeted TB drug with a novel mechanism of action to be approved in more than 40 years.

Today, our TB medicine is approved in many countries around the world, including in many high-burden countries, and registration efforts are ongoing in several others. It is also available in dozens more countries procuring the medicine through the Stop TB Partnership’s Global Drug Facility.

By the Numbers

Courses of our medicine delivered to date
Courses of our medicine provided for free through a four-year donation program
Countries accessing our medicine, including the 30 highest-burden countries
Countries in which our medicine has been approved

Our 10-Year Initiative

In September 2018, Johnson & Johnson reaffirmed its continued commitment to the fight against TB by announcing a new 10-year initiative with three pillars:

  • Expanding access to treatment by offering a not-for-profit price to 130+ low- and middle-income countries, as well as nongovernmental organizations, procuring our medicine through the Stop TB Partnership’s Global Drug Facility
  • Improving case finding and strengthening health systems to reach the thousands of people with undiagnosed TB and MDR-TB and connect them to care, including by improving diagnostic capacity, training health workers and raising community awareness
  • Accelerating TB research and development (R&D) to discover innovative next-generation treatments that will be needed to reach the global goal of ending TB

Our Latest News

Learn Why Now’s the Time to Act

Pathway to Progress

New Compound Is Identified

Janssen identifies a compound that would ultimately be developed as our new therapy for MDR-TB.

Janssen’s MDR-TB Medicine Shows Promise

The Janssen team publishes a study in the medical journal Science showing that our medicine successfully treats MDR-TB in mice.

Janssen Partners With TB Alliance

Janssen enters into a license and collaboration agreement with the TB Alliance focused on the development of our MDR-TB medicine for drug-sensitive TB.

Medicine Receives Accelerated Approval

Our MDR-TB medicine is granted accelerated approval by the U.S. FDA as the first targeted drug with a novel mechanism of action against TB in more than 40 years.

Janssen Enters Collaboration With Stichting International Dispensary Association

This partnership with a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF) helps to facilitate access to the company’s MDR-TB medicine.

Johnson & Johnson Launches Innovative Partnership With USAID

The company commits to provide up to 30,000 courses of MDR-TB medicine, free of charge, in eligible low- and middle-income countries through a donation program with the United States Agency for International Development (USAID).

Johnson & Johnson Forms Innovative Partnership With Pharmstandard

The company enters an agreement with Pharmstandard to register and commercialize MDR-TB medicine and donate nearly 6,000 courses of treatment over four years in Russia and other countries in the region.

Janssen Partners With Institute of Microbial Technology

Janssen signs a Memorandum of Understanding with India’s Institute of Microbial Technology to develop safer, shorter and more effective TB treatments and multidrug regimens.

Johnson & Johnson Announces Extension of Donation Program

In response to high demand, Johnson & Johnson commits to provide an additional 30,000 courses of treatment through March 2019 via a donation program with USAID and Pharmstandard.

South African Government Leads the Way

South Africa becomes the first country to recommend a bedaquiline-containing, injection-free regimen for all eligible MDR-TB patients.

Johnson & Johnson Offers Special Effort Price for Low- and Middle-Income Countries

In recognition of South Africa’s leadership, Johnson & Johnson announces a new single-channel price for eligible national TB programs and NGOs procuring our treatment through the Stop TB Partnership’s Global Drug Facility.

New Study Shows Cost Effectiveness of Our MDR-TB Medicine

A new cost-effectiveness study suggests both long- and short-course regimens containing our MDR-TB drug, without injectables, are cost-effective and provide significant health system savings.

WHO Announces Revised Treatment Guidelines for MDR-TB

The World Health Organization announces revised treatment guidelines for MDR-TB that categorize our medicine as a “Group A” medicine to be prioritized when constructing a conventional (long-course) regimen for MDR-TB.

Johnson & Johnson Announces 10-year TB Initiative

Johnson & Johnson announces new 10-year TB initiative aimed at improving case finding, expanding treatment access and advancing R&D

J&J-Supported EIU Report Launches

Report estimates DR-TB deaths in a single year cost the global economy at least US$17.8 billion and calls for action to end the epidemic.

January 2002

January 2005

June 2009

December 2012

April 2014

April 2015

December 2015

August 2017

May 2018

June 2018

July 2018

August 2018

August 2018

September 2018

May 2019

Champions to #ENDTB

To end TB, we urgently need to bring forward a new generation of treatments and multidrug regimens that are shorter, safer and more effective than many of the drugs currently used to treat the disease.

At Johnson & Johnson, our top priority is developing and delivering medicines to all patients in need. We stand committed to working closely with countries and other partners to rapidly scale up access to bedaquiline and reach all eligible patients.

Our mission has always been to ensure that patients have access to the best and most innovative TB treatment. I am confident that together with our global partners, we can achieve our ambitious goal of ending TB by 2030.

It has been an honor to be part of the team that worked to develop the first novel medicine for patients with multidrug-resistant tuberculosis in the last 40 years. Our achievement highlights the importance of research to improve global public health and reinforces Johnson & Johnson’s commitment to Our Credo: patients come first.

Innovative Research Around the World

Report notes gaps in world’s response to drug-resistant TB
Report offers annual assessments of TB epidemic.
Plan provides five-year road map for the fight against TB.
Led by the UN and KPMG to convert interest in Sustainable Development Goals into strategic activities.
Examining role and definition of core and companion drugs.
Study says newer drugs may have more robust efficacy data.
Study says there is an expanding body of evidence on the events caused by these drugs.
Study describes case detection and patient outcomes in a community-based program.
Study finds link with faster conversion in patients with multidrug-resistant tuberculosis.
Study found improved cure rates when added to multidrug-resistant treatment regimen.
This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.